
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is positioned for success in the biotechnology industry with its strong pipeline of precision oncology therapies. The company's collaborations and license revenue, coupled with its positive clinical data, demonstrate its potential for growth. The potential for a strategic partnership or acquisition, and the potential for vopimetostat to become a first-line therapy for KRAS-mutated pancreatic cancer further support our positive outlook for Tango Therapeutics.
Bears say
Tango Therapeutics is a pre-commercial biotech company with a negative outlook due to several key factors. These include the potential for negative clinical results with lead asset TNG462, risks associated with advancing pipeline candidates, and the potential for failure to achieve favorable clinical results with other candidates. Additionally, the company may face significant competition in the oncology market, which could impact its revenue potential. There is also a possibility that the FDA could delay or reject approval of vopimetostat, creating downside risk for the company. Given these factors, the high valuation and price target for Tango Therapeutics may not be achievable.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares